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the changing landscape for research and development in the pharma-ceutical and food industries, coupled with changing societal attitudes and requirements, creates new challenges and opportunities for industry-academe 
collaborations. The case of alimentary pharmabiotics is a representative niche area with 
opportunities for both industrial sectors. although manipulation of the gut microbiota 
in the treatment and prevention of several disorders has become a plausible strategy, a 
more intriguing prospect is the potential to “mine’’ diet-host-microbe interactions for 
functional food ingredients and for novel discovery.  
Changing Landscapes
as the pharmaceutical industry faces increasing challenges in drug discovery, new models 
for research and development (r&D) are called for (Crommelin et al., 00; Shah et al., 
00). The landscape today is dominated by declining output of new molecular entities, 
more outsourcing of r&D, partnerships and alliances, increasing emphasis on biologics 
over small molecules and a commercial imperative for agility and flexibility. at the same 
time, advances in understanding major disease processes promise to open the way for 
definition of subsets of patients at a molecular level, with genotyping replacing historic 
approaches to phenotyping diseases. This will tend to fragment the industry’s mass markets 
into genotype segments and will undermine the old blockbuster model (“one-size-fits-all 
drug”) with a new era of personalized medicine. 
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The degree to which this brave new world will prevail is likely to vary for different 
diseases, and will be influenced by societal attitudes toward the treatment and prevention 
of disease, in particular, depending on whether a pharmacological or non-pharmacologi-
cal approach is favored (Crommelin et al. 00). The pharma sector is likely to remain 
dominant in innovation and may engage with academia in pursuit of solutions for chronic 
inflammatory, infectious and neoplastic diseases. for other disorders, particularly where 
alternatives to drug treatment are desired, small companies, academia and publicly funded 
institutions are likely to take a leading position with declining involvement of big pharma. 
examples of the latter may include the exploration of functional-food ingredients or the 
pursuit of remedies for heterogeneous “functional” disorders and for those euphemistically 
referred to as “lifestyle” disorders (Crommelin et al. 00).
against these changing scenarios, opportunities for the food industry, especially in the 
functional-food business, must be considered in light of greater regulatory constraints, 
more stringent requirements for claims on food products, and a modern society that is risk 
averse. Thus, the distinction between a functional-food ingredient and a drug becomes 
blurred. furthermore, pressure to control prices and focus on niche markets will affect 
both the food and pharma industries. 
opportunities for industry-academe interactions in both the food and pharma sectors 
will flourish, provided an entrepreneurial approach to science is encouraged, and where 
academic institutions provide for greater flexibility and agility in adapting to change. The 
case of alimentary pharmabiotics, as an example of a common ground for the food and 
pharmaceutical industries to explore in collaboration with academia, is summarized below.
alimentary Pharmabiotics
Despite major technologic and conceptual advances in biology, new drug development 
in gastroenterology appears to be in decline (Parsons and Garner, 995; Caskey, 00). 
while large fortunes have been expended by the pharmaceutical industry in synthetic-
drug development, it is noteworthy that about half of the drugs approved by the food 
and Drug administration (fDa) in the United States in the past twenty-five years have 
been derived from natural living material in the wider environment (newman and 
Cragg, 00; Bernstein and Ludwig, 00). Therefore, it seems logical and timely that 
the inner microenvironment of the alimentary tract might be another rich repository 
from which functional-food ingredients and new drugs can be mined (Shanahan et al., 
009; Shanahan, 00). 
an alimentary “pharmabiotic” is the name that we have given to products derived 
from mining host-microbe interactions in the gut that have a proven health benefit. 
This encompassing neologism overcomes the limitations of restrictive definitions of 
probiotics, prebiotics, synbiotics and postbiotics. Thus, it embraces whole organisms, 
live or dead, components and metabolites thereof, and genetically modified organisms 
and the concept has the potential for translation to the marketplace by either the food or 
pharmaceutical industry. representative examples of the potential for mining microbe-
microbe interactions, host-microbe and diet-host-microbe interactions in the gut are 
summarized in table . 
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whether pharmabiotics mined from the natural environment of the gut will be exploited 
by the food or the pharma sector will depend in part on whether a small molecular entity 
or a bacterial fragment is involved, the nature of the desired effect, and the clinical indica-
tion. The clearest delineation will be the treatment of established disease or biomarkers of 
early disease in the case of the pharmaceutical sector, whereas the food industry is more 
likely to focus on disease prevention as measured by reduction in a biomarker of risk. 
opportunities for academic collaborations exist in both scenarios. to that end, academic 
research centres, such as the alimentary Pharmabiotic Centre (http://www.ucc.ie/research/
apc/), have espoused the virtues of hybrid science and hybrid scientists capable of working 
across the boundaries of traditional disciplines and at the food-pharma interface. These 
include scientists, clinicians, and clinician-scientists with the collective ability to bring 
scientific ideas from the laboratory through the clinic to the bedside and marketplace. 
research in academic centers can be aligned to simultaneously suit the requirements of 
both the food and pharma industrial sectors while fostering an environment conducive 
to entrepreneurship and freshness of ideas. for those who doubt it can be done—it can 
be done because it is being done!   
Table 1. opporTuniTies for “mining” The guT microbioTa 
for pharmabioTics.
Interaction Pharmabiotic Reference
Microbe-microbe
Host-microbe
Diet-host-
microbe
exploration of bacteriocins against
specific pathogens (e.g. Clostridium 
 difficile)
anti-inflammatory drugs from bacterial 
components or metabolites that modify 
mucosal inflammation (e.g. lipoteichoic 
acid, CpG Dna)
Immunomodulatory drugs from bacterial
cell-wall polysaccharides
analgesic activities (some but not all
probiotics are beneficial in irritable
bowel syndrome and visceral
hyperalgesia)
Manipulation of the microbiota may
alter bioavailability of dietary calories
Interaction between the microbiota and
dietary components may alter the
composition of host adipose tissue.
rea et al. (00)
Grangette et al. (005);
obermeier et al. (003)
rachmilewitz et al. (00)
Mazmanian et al. (005, 00)
rousseaux et al. (00)
Bakhed et al. (00)
wall et al. (009)
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